Developer docs
API playgroundTry for free, no card

Search company profiles

BioDlink

Full company profile

uuid003pwbc

Namestring
BioDlink
Legal namestring
BioDlink International Company Limited
Websiteurl
biodlink.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

BioDlink is an integrated biologics and antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) headquartered in Suzhou Industrial Park, China. Founded in 2010 and listed on the Hong Kong Stock Exchange (ticker 1875.HK) since November 2019, the company operates a one-stop CDMO platform spanning cell line development, antibody manufacturing, conjugation process development, drug product formulation, lyophilization, and commercial GMP manufacturing. Its proprietary technology stack includes the GL-DisacLink® glycan-specific ADC conjugation platform (co-developed with Tangling Bio), the BDKcell® CHO-K1 cell line platform with reported 8-10 g/L antibody titers, the BDKLyo™ digital lyophilization modeling platform, and an OS one-step conjugation technology. BioDlink maintains 20,000+ L of monoclonal antibody manufacturing capacity, 960 kg of ADC drug substance capacity, and 4 commercial-scale production lines, with quality systems certified to FDA, EMA, NMPA, PMDA, ANVISA, and EU QP standards.

The company's revenue model combines project-based CDMO service fees (fixed-fee and milestone-based contracts tied to project progression and regulatory achievements) with revenue from proprietary commercial products including the bevacizumab biosimilar Pusintin and MEIYOUHENG (Becotatug Vedotin), the world's first EGFR-targeted ADC developed with Lepu Biopharma. As of 2025, BioDlink had served 108 cumulative clients across 213 projects, with ADC-related projects comprising 68% of the pipeline and overseas clients representing 19% of the client base. The company pursues a sales-led go-to-market model with dedicated business development teams engaging global biopharmaceutical clients at major industry events and through direct enterprise outreach, supported by technical publications and conference presence.

Following a strategic 2020 pivot from biosimilars to ADC-focused CDMO services under CEO Dr. Liu Jun, BioDlink materially expanded its ADC platform, secured multiple international GMP certifications, and signed a RMB 3.08 billion order backlog (up 61% YoY). In late 2025, WuXi XDC (HKG: 2268) completed a $400 million voluntary offer for BioDlink, making it a controlled subsidiary and integrating it into WuXi XDC's broader ADC/XDC CRDMO platform as of June 2026.

Short descriptiontext

BioDlink is an integrated biologics and ADC-focused CDMO providing one-stop development, GMP manufacturing, and commercial supply services from cell line to drug product. It serves global biopharmaceutical clients with proprietary conjugation, cell line, and digital lyophilization platforms, operating as a controlled subsidiary of WuXi XDC.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSuzhou, China
HQ citystring
Suzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics CDMO services, ADC contract manufacturing, antibody drug development, lyophilization formulation, monoclonal antibody production
Industry2 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Biologics Contract Development and Manufacturing (CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1CDMO/CMO Services
TypeProfessional Services
Description

Contract development and manufacturing organization services for biologics including ADC, monoclonal antibodies, and other biological drugs. Services span from early R&D, process development, analytical method development, GMP manufacturing, to regulatory filing support. Revenue is project-based with a mix of fixed-fee contracts for defined services and milestone-based payments tied to project progress and regulatory achievements.

biodlink.com
2Product Sales
TypeOne Time License
Description

Sales of proprietary biological drugs including bevacizumab biosimilar (朴欣汀/Pusintin), which has been approved in multiple countries internationally. Also includes other marketed products.

biodlink.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details1 tier
1Project-based CDMO service pricing tailored to client requirements
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies based on project scope including molecule type (ADC, mAb, etc.), development stage (early R&D, clinical, commercial), service types required, batch sizes, and regulatory pathways. No public price list available.

biodlink.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1BDKcell CHO-K1
Description

Proprietary cell line development platform with optimized CHO-K1 cell system, featuring short development cycle, high expression, and good stability

biodlink.com
+4 more records
Core offering1 text field

BioDlink is a biologics Contract Development and Manufacturing Organization (CDMO) providing one-stop services spanning antibody R&D, cell line development, ADC conjugation process development, drug substance and drug product manufacturing, lyophilization, analytical method development, technology transfer, and regulatory affairs support. The company operates an integrated ADC/XDC CRDMO platform with over 20,000 L of monoclonal antibody manufacturing capacity and 960 kg of ADC drug substance capacity, serving global biopharmaceutical clients from early R&D through commercial manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Successfully enabled the world's first EGFR-targeted ADC drug (Becotatug Vedotin) commercial launch in China, marking first CDMO-manufactured ADC to receive approval.
+4 more records
Product overview1 text field

BioDlink is a biologics CDMO (Contract Development and Manufacturing Organization) providing one-stop CDMO solutions. The company operates a platform-plus-services model centered on its ADC Integrated Platform, which encompasses R&D services, conjugation process development, drug formulation and lyophilization, and analysis services. Supporting platforms include the Protein/Antibody Platform (cell culture and purification), GMP Manufacturing (20,000+ L capacity), Technology Transfer, Quality Management, and Regulatory Affairs services. The company also offers proprietary technology platforms including GL-DisacLink® for glycan site-specific ADC conjugation, BDKcell® CHO-K1 cell line development, and BDKLyo™ digital lyophilization optimization. Commercial products include MEIYOUHENG (Becotatug Vedotin), the world's first EGFR-targeted ADC, and 朴欣汀® (Pusintin), a bevacizumab biosimilar.

Product and service6 records
1ADC Integrated Platform
CategoryBiologics CDMO Services
Description

R&D, process development, and commercial manufacturing platform for ADC including monoclonal antibody production, drug substance (DS), and drug product (DP). Covers conjugation process development, formulation, lyophilization, and analysis services for biopharmaceutical clients developing ADC drugs.

2Protein/Antibody Platform
CategoryBiologics CDMO Services
Description

Cell culture process development, purification process development, lyophilization process, and analysis services for proteins and antibodies based on QbD concept. Designed for biopharmaceutical clients developing monoclonal antibodies, bispecific antibodies, and fusion proteins.

3GMP Manufacturing
CategoryContract Manufacturing
Description

Large-scale commercial GMP production base for biological drugs with multiple complete upstream and downstream production lines. Total manufacturing capacity exceeds 20,000 L for monoclonal antibodies and 960 kg for ADC drug substance, including drug substance and drug product manufacturing.

4Technology Transfer
CategoryBiologics CDMO Services
Description

Efficient technology transfer services based on mutual trust and reasonable control strategies, ensuring smooth project implementation between clients' R&D processes and BioDlink's manufacturing scale-up.

5Quality Management
CategoryQuality and Compliance Services
Description

GMP-compliant quality management system conforming to commercial manufacturing standards, running through from R&D to commercialization, supporting multiple marketed products. Includes Quality Control and Quality Assurance functions compliant with FDA, EMA, and NMPA regulations.

6Regulatory Affairs
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-04-20
Description

CDMO partnership for AK0406 Antiviral Fc Conjugate (AFC) drug for influenza treatment. BioDlink provided full-chain development from cell line development, process development, analytical method establishment, formulation development to clinical sample production, completing the entire process within 12 months.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-09
Description

CDMO partnership for KH815 dual-payload ADC development. BioDlink completed process development, manufacturing, and regulatory submission activities for this world's first dual-payload ADC to enter clinical trials, finishing 1.5 months ahead of schedule.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-16
Description

WuXi XDC made a voluntary offer to acquire BioDlink for approximately $400 million. WuXi XDC completed acquisition of BioDlink's Suzhou site and became a controlled subsidiary in 2026, with BioDlink continuing to operate as part of WuXi XDC's integrated ADC/XDC CRDMO platform.

4Lepu Biopharma (乐普生物)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-12
Description

Strategic CDMO partnership for the development and manufacturing of Becotatug Vedotin (美佑恒), the world's first EGFR-targeted ADC drug. BioDlink provided end-to-end services from technology transfer, clinical sample production, PPQ batches, PAI inspection support, to BLA filing, culminating in NMPA approval in October 2025. The successful collaboration marked both the world's first EGFR ADC approval and the first ADC drug in China fully manufactured by a CDMO partner.

prnewswire.com
5Hutchmed (和黄医药)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-11-12
Description

CDMO service partnership for multiple projects including key ADC products. BioDlink was awarded 'Best Collaboration Partner' by Hutchmed for service excellence on both projects.

biodlink.com
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-11-05
Description

Technology licensing partnership for WuXiTecan-2 with potential consideration up to US$885 million, as part of WuXi XDC's strategic technology expansion.

7Kexing BioPharm (科兴制药)
Strategic tierStrategicTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-27
Description

Partnership for international commercialization of bevacizumab biosimilar in emerging markets. Kexing leverages its overseas registration and channel advantages for rapid market access in Latin America and other regions, while BioDlink provides manufacturing. Bevacizumab approved in 5 countries including Nigeria, Pakistan, Colombia, Indonesia, and Bolivia.

prnewswire.com
8Yibu Bio (宜联生物)
Strategic tierStrategicTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-10-18
Description

Partnership where Yibu Bio partnered with BioNTech for HER3-targeted ADC development. BioDlink provides CDMO services including GMP formulation production for Yibu Bio's ADC pipeline.

biodlink.com
9HaoYuan Pharmaceutical (皓元医药)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-09-19
Description

Strategic partnership to create a comprehensive ADC CDMO service platform. BioDlink provides mAb production and ADC CMC development while HaoYuan provides linker, payload, and Payload-Linker intermediates, enabling end-to-end services from R&D to industrialization.

10TangLing Bio (糖岭生物)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-07-05
Description

Strategic partnership for DisacLink™ glycan-specific ADC conjugation technology. Joint technology development, process optimization and commercialization scaling. BioDlink licensed to use DisacLink™ platform for CDMO services, providing industrial manufacturing capability for this advanced conjugation technology.

biodlink.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-05-19
Description

Full-spectrum CDMO strategic partnership for ADC development and commercialization. BioDlink provides one-stop, end-to-end CDMO platform services for multiple ADC R&D projects, supporting pipeline from development through IND and future commercial manufacturing.

12Jeminia (济民可信)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-01-05
Description

Strategic CDMO partnership for drug R&D and commercial manufacturing. Previously completed COVID-19 neutralizing antibody JMB2002 commercial scale-up 1.5 months ahead of schedule. The partnership was formalized into a broader strategic collaboration agreement.

biodlink.com
13Bochu Bio (博瑞医药)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2021-07-19
Description

Strategic ADC CDMO partnership combining BioDlink's monoclonal antibody production and ADC CMC process development with Bochu's linker and payload intermediate capabilities. Both companies are located in Suzhou Industrial Park, enabling seamless supply chain integration and reducing cross-regional regulatory risks.

biodlink.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in biologics manufacturing with extensive mammalian cell culture capacity. Offers comparable CDMO services (cell line, process development, GMP manufacturing) at much larger scale. Represents the gold standard incumbent that BioDlink competes against in international markets.

TypeBroad incumbent
Description

Global leader in biologics CDMO services and parent of WuXi XDC (which owns BioDlink). Offers end-to-end biologics development and manufacturing. Comparable to BioDlink on the biologics manufacturing side, though broader and more established in mAb CDMO services.

TypeDirect peer
Description

China-headquartered CRO/CDMO offering biologics and small molecule development and manufacturing services. Comparable to BioDlink's integrated service model and target customer base of biotech companies seeking CDMO partnerships in Asia.

TypeBroad incumbent
Description

Major Asian-headquartered biologics CDMO with very large-scale mammalian manufacturing capacity. Comparable in terms of biologics manufacturing focus and Asian geographic positioning, though significantly larger and more established than BioDlink.

TypeBroad incumbent
Description

Thermo Fisher's CDMO business offering biologics and small molecule manufacturing services globally. Comparable in terms of integrated CDMO service model across drug substance and drug product, though operates at vastly larger scale with broader service portfolio.

6TOT Biopharma
TypeDirect peer
Description

Hong Kong-listed Chinese biologics CDMO offering antibody drug substance and drug product manufacturing, with PMDA foreign manufacturer accreditation. Direct peer to BioDlink in the Chinese biologics CDMO market with similar size and customer profile (some sources reference TOT BIOPHARM in connection with BioDlink's PMDA accreditation).

TypeDirect peer
Description

Global biologics CDMO offering microbial and mammalian cell culture-based manufacturing, including cell therapy services. Direct peer in the biologics CDMO space with similar service offerings (cell line development, process development, GMP manufacturing) and comparable customer profile.

TypeDirect peer
Description

Direct peer and now parent company. WuXi XDC is a Hong Kong-listed CRDMO focused on ADC and bioconjugates, offering antibody, conjugation, and drug product services. Most directly comparable to BioDlink given overlapping ADC CDMO capabilities and shared customer base, including the recent $400M acquisition of BioDlink.

TypeBroad incumbent
Description

Global CDMO offering biologics, cell therapy, and drug product services including lyophilization. Recently acquired by Novo Holdings. Comparable to BioDlink's drug product formulation and lyophilization services, plus broader biologics CDMO offerings.

TypeDirect peer
Description

China-based biologics CDMO offering cell line development, plasmid/mRNA, viral vector, and protein manufacturing services. Direct competitor to BioDlink in the Chinese biologics CDMO market with similar target customers (Chinese and international biotech companies developing biologics).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance11 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioDlink

Biologics Contract Development and Manufacturing (CDMO)biodlink.com

BioDlink is an integrated biologics and ADC-focused CDMO providing one-stop development, GMP manufacturing, and commercial supply services from cell line to drug product. It serves global biopharmaceutical clients with proprietary conjugation, cell line, and digital lyophilization platforms, operating as a controlled subsidiary of WuXi XDC.

What BioDlink does

BioDlink is an integrated biologics and antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) headquartered in Suzhou Industrial Park, China. Founded in 2010 and listed on the Hong Kong Stock Exchange (ticker 1875.HK) since November 2019, the company operates a one-stop CDMO platform spanning cell line development, antibody manufacturing, conjugation process development, drug product formulation, lyophilization, and commercial GMP manufacturing. Its proprietary technology stack includes the GL-DisacLink® glycan-specific ADC conjugation platform (co-developed with Tangling Bio), the BDKcell® CHO-K1 cell line platform with reported 8-10 g/L antibody titers, the BDKLyo™ digital lyophilization modeling platform, and an OS one-step conjugation technology. BioDlink maintains 20,000+ L of monoclonal antibody manufacturing capacity, 960 kg of ADC drug substance capacity, and 4 commercial-scale production lines, with quality systems certified to FDA, EMA, NMPA, PMDA, ANVISA, and EU QP standards.

The company's revenue model combines project-based CDMO service fees (fixed-fee and milestone-based contracts tied to project progression and regulatory achievements) with revenue from proprietary commercial products including the bevacizumab biosimilar Pusintin and MEIYOUHENG (Becotatug Vedotin), the world's first EGFR-targeted ADC developed with Lepu Biopharma. As of 2025, BioDlink had served 108 cumulative clients across 213 projects, with ADC-related projects comprising 68% of the pipeline and overseas clients representing 19% of the client base. The company pursues a sales-led go-to-market model with dedicated business development teams engaging global biopharmaceutical clients at major industry events and through direct enterprise outreach, supported by technical publications and conference presence.

Following a strategic 2020 pivot from biosimilars to ADC-focused CDMO services under CEO Dr. Liu Jun, BioDlink materially expanded its ADC platform, secured multiple international GMP certifications, and signed a RMB 3.08 billion order backlog (up 61% YoY). In late 2025, WuXi XDC (HKG: 2268) completed a $400 million voluntary offer for BioDlink, making it a controlled subsidiary and integrating it into WuXi XDC's broader ADC/XDC CRDMO platform as of June 2026.

BioDlink firmographics

Firmographics
Name
BioDlink
Legal name
BioDlink International Company Limited
Website
https://biodlink.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
BioDlink is an integrated biologics and ADC-focused CDMO providing one-stop development, GMP manufacturing, and commercial supply services from cell line to drug product. It serves global biopharmaceutical clients with proprietary conjugation, cell line, and digital lyophilization platforms, operating as a controlled subsidiary of WuXi XDC.
Ownership category
akta.pro rank

BioDlink industry classification

Industry
Product category
Biologics Contract Development and Manufacturing (CDMO)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Biologics CDMO services
  • ADC contract manufacturing
  • Antibody drug development
  • Lyophilization formulation
  • Monoclonal antibody production

Where BioDlink is headquartered

Location

Headquarters

HQ city
Suzhou
HQ country
China
HQ region
Asia

Offices4 records

Markets served

BioDlink business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. CDMO/CMO Services: Contract development and manufacturing organization services for biologics including ADC, monoclonal antibodies, and other biological drugs. Services span from early R&D, process development, analytical method development, GMP manufacturing, to regulatory filing support. Revenue is project-based with a mix of fixed-fee contracts for defined services and milestone-based payments tied to project progress and regulatory achievements.
  2. Product Sales: Sales of proprietary biological drugs including bevacizumab biosimilar (朴欣汀/Pusintin), which has been approved in multiple countries internationally. Also includes other marketed products.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based CDMO service pricing tailored to client requirements

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

BioDlink product offering

Product offering

Core offering

BioDlink is a biologics Contract Development and Manufacturing Organization (CDMO) providing one-stop services spanning antibody R&D, cell line development, ADC conjugation process development, drug substance and drug product manufacturing, lyophilization, analytical method development, technology transfer, and regulatory affairs support. The company operates an integrated ADC/XDC CRDMO platform with over 20,000 L of monoclonal antibody manufacturing capacity and 960 kg of ADC drug substance capacity, serving global biopharmaceutical clients from early R&D through commercial manufacturing.

Product overview

BioDlink is a biologics CDMO (Contract Development and Manufacturing Organization) providing one-stop CDMO solutions. The company operates a platform-plus-services model centered on its ADC Integrated Platform, which encompasses R&D services, conjugation process development, drug formulation and lyophilization, and analysis services. Supporting platforms include the Protein/Antibody Platform (cell culture and purification), GMP Manufacturing (20,000+ L capacity), Technology Transfer, Quality Management, and Regulatory Affairs services. The company also offers proprietary technology platforms including GL-DisacLink® for glycan site-specific ADC conjugation, BDKcell® CHO-K1 cell line development, and BDKLyo™ digital lyophilization optimization. Commercial products include MEIYOUHENG (Becotatug Vedotin), the world's first EGFR-targeted ADC, and 朴欣汀® (Pusintin), a bevacizumab biosimilar.

Differentiator

Problem solved

Functional benefit

Brands

  • BDKcell CHO-K1: Proprietary cell line development platform with optimized CHO-K1 cell system, featuring short development cycle, high expression, and good stability
  • BDKLyo™
  • GL-DisacLink®
  • 朴欣汀 (Pusintin)
  • 美佑恒 (MEIYOUHENG)

Products and services

  • ADC Integrated Platform R&D, process development, and commercial manufacturing platform for ADC including monoclonal antibody production, drug substance (DS), and drug product (DP). Covers conjugation process development, formulation, lyophilization, and analysis services for biopharmaceutical clients developing ADC drugs.
  • Protein/Antibody Platform Cell culture process development, purification process development, lyophilization process, and analysis services for proteins and antibodies based on QbD concept. Designed for biopharmaceutical clients developing monoclonal antibodies, bispecific antibodies, and fusion proteins.
  • GMP Manufacturing Large-scale commercial GMP production base for biological drugs with multiple complete upstream and downstream production lines. Total manufacturing capacity exceeds 20,000 L for monoclonal antibodies and 960 kg for ADC drug substance, including drug substance and drug product manufacturing.
  • Technology Transfer Efficient technology transfer services based on mutual trust and reasonable control strategies, ensuring smooth project implementation between clients' R&D processes and BioDlink's manufacturing scale-up.
  • Quality Management GMP-compliant quality management system conforming to commercial manufacturing standards, running through from R&D to commercialization, supporting multiple marketed products. Includes Quality Control and Quality Assurance functions compliant with FDA, EMA, and NMPA regulations.
  • Regulatory Affairs

Quantifiable outcome

  • Successfully enabled the world's first EGFR-targeted ADC drug (Becotatug Vedotin) commercial launch in China, marking first CDMO-manufactured ADC to receive approval.
  • +4 more outcomes

Companies that use BioDlink

Customer profile

Named customers11 records

Segments1 record

Ideal customer profiles3 records

BioDlink technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature9 records

BioDlink partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered strategic and core.

  • Akesobio (爱科百发)strategicStrategic or Co-development Partner · 20 April 2026CDMO partnership for AK0406 Antiviral Fc Conjugate (AFC) drug for influenza treatment. BioDlink provided full-chain development from cell line development, process development, analytical method establishment, formulation development to clinical sample production, completing the entire process within 12 months.
  • Chengdu Kanghong Pharmaceutical (成都康弘药业)coreStrategic or Co-development Partner · 9 February 2026CDMO partnership for KH815 dual-payload ADC development. BioDlink completed process development, manufacturing, and regulatory submission activities for this world's first dual-payload ADC to enter clinical trials, finishing 1.5 months ahead of schedule.
  • WuXi XDCcoreStrategic or Co-development Partner · 16 January 2026WuXi XDC made a voluntary offer to acquire BioDlink for approximately $400 million. WuXi XDC completed acquisition of BioDlink's Suzhou site and became a controlled subsidiary in 2026, with BioDlink continuing to operate as part of WuXi XDC's integrated ADC/XDC CRDMO platform.
  • Lepu Biopharma (乐普生物)coreStrategic or Co-development Partner · 12 November 2025Strategic CDMO partnership for the development and manufacturing of Becotatug Vedotin (美佑恒), the world's first EGFR-targeted ADC drug. BioDlink provided end-to-end services from technology transfer, clinical sample production, PPQ batches, PAI inspection support, to BLA filing, culminating in NMPA approval in October 2025. The successful collaboration marked both the world's first EGFR ADC approval and the first ADC drug in China fully manufactured by a CDMO partner.
  • Hutchmed (和黄医药)strategicStrategic or Co-development Partner · 12 November 2025CDMO service partnership for multiple projects including key ADC products. BioDlink was awarded 'Best Collaboration Partner' by Hutchmed for service excellence on both projects.
  • Earendil LabsstrategicTechnology or Integration · 5 November 2025Technology licensing partnership for WuXiTecan-2 with potential consideration up to US$885 million, as part of WuXi XDC's strategic technology expansion.
  • Kexing BioPharm (科兴制药)strategicChannel Partner/ Reseller/ Distributor · 27 October 2025Partnership for international commercialization of bevacizumab biosimilar in emerging markets. Kexing leverages its overseas registration and channel advantages for rapid market access in Latin America and other regions, while BioDlink provides manufacturing. Bevacizumab approved in 5 countries including Nigeria, Pakistan, Colombia, Indonesia, and Bolivia.
  • Yibu Bio (宜联生物)strategicChannel Partner/ Reseller/ Distributor · 18 October 2023Partnership where Yibu Bio partnered with BioNTech for HER3-targeted ADC development. BioDlink provides CDMO services including GMP formulation production for Yibu Bio's ADC pipeline.
  • HaoYuan Pharmaceutical (皓元医药)strategicStrategic or Co-development Partner · 19 September 2023Strategic partnership to create a comprehensive ADC CDMO service platform. BioDlink provides mAb production and ADC CMC development while HaoYuan provides linker, payload, and Payload-Linker intermediates, enabling end-to-end services from R&D to industrialization.
  • TangLing Bio (糖岭生物)strategicStrategic or Co-development Partner · 5 July 2023Strategic partnership for DisacLink™ glycan-specific ADC conjugation technology. Joint technology development, process optimization and commercialization scaling. BioDlink licensed to use DisacLink™ platform for CDMO services, providing industrial manufacturing capability for this advanced conjugation technology.
  • BioRay Bio (博锐生物)strategicStrategic or Co-development Partner · 19 May 2023Full-spectrum CDMO strategic partnership for ADC development and commercialization. BioDlink provides one-stop, end-to-end CDMO platform services for multiple ADC R&D projects, supporting pipeline from development through IND and future commercial manufacturing.
  • Jeminia (济民可信)strategicStrategic or Co-development Partner · 5 January 2022Strategic CDMO partnership for drug R&D and commercial manufacturing. Previously completed COVID-19 neutralizing antibody JMB2002 commercial scale-up 1.5 months ahead of schedule. The partnership was formalized into a broader strategic collaboration agreement.
  • Bochu Bio (博瑞医药)strategicStrategic or Co-development Partner · 19 July 2021Strategic ADC CDMO partnership combining BioDlink's monoclonal antibody production and ADC CMC process development with Bochu's linker and payload intermediate capabilities. Both companies are located in Suzhou Industrial Park, enabling seamless supply chain integration and reducing cross-regional regulatory risks.

Scale indicators14 records

Recent moves9 records

Expansion highlights6 records

BioDlink competitors and assessment

Company assessment

Broad incumbents

  • Lonza Biologics: Global leader in biologics manufacturing with extensive mammalian cell culture capacity. Offers comparable CDMO services (cell line, process development, GMP manufacturing) at much larger scale. Represents the gold standard incumbent that BioDlink competes against in international markets.
  • WuXi Biologics: Global leader in biologics CDMO services and parent of WuXi XDC (which owns BioDlink). Offers end-to-end biologics development and manufacturing. Comparable to BioDlink on the biologics manufacturing side, though broader and more established in mAb CDMO services.
  • Samsung Biologics: Major Asian-headquartered biologics CDMO with very large-scale mammalian manufacturing capacity. Comparable in terms of biologics manufacturing focus and Asian geographic positioning, though significantly larger and more established than BioDlink.
  • Patheon (Thermo Fisher): Thermo Fisher's CDMO business offering biologics and small molecule manufacturing services globally. Comparable in terms of integrated CDMO service model across drug substance and drug product, though operates at vastly larger scale with broader service portfolio.
  • Catalent (Novo Holdings): Global CDMO offering biologics, cell therapy, and drug product services including lyophilization. Recently acquired by Novo Holdings. Comparable to BioDlink's drug product formulation and lyophilization services, plus broader biologics CDMO offerings.

Direct peers

  • Pharmaron: China-headquartered CRO/CDMO offering biologics and small molecule development and manufacturing services. Comparable to BioDlink's integrated service model and target customer base of biotech companies seeking CDMO partnerships in Asia.
  • TOT Biopharma: Hong Kong-listed Chinese biologics CDMO offering antibody drug substance and drug product manufacturing, with PMDA foreign manufacturer accreditation. Direct peer to BioDlink in the Chinese biologics CDMO market with similar size and customer profile (some sources reference TOT BIOPHARM in connection with BioDlink's PMDA accreditation).
  • AGC Biologics: Global biologics CDMO offering microbial and mammalian cell culture-based manufacturing, including cell therapy services. Direct peer in the biologics CDMO space with similar service offerings (cell line development, process development, GMP manufacturing) and comparable customer profile.
  • WuXi XDC: Direct peer and now parent company. WuXi XDC is a Hong Kong-listed CRDMO focused on ADC and bioconjugates, offering antibody, conjugation, and drug product services. Most directly comparable to BioDlink given overlapping ADC CDMO capabilities and shared customer base, including the recent $400M acquisition of BioDlink.
  • Genscript ProBio: China-based biologics CDMO offering cell line development, plasmid/mRNA, viral vector, and protein manufacturing services. Direct competitor to BioDlink in the Chinese biologics CDMO market with similar target customers (Chinese and international biotech companies developing biologics).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

BioDlink social profiles

Digital presence

BioDlink compliance and trust

Trust signal

Compliance11 records

BioDlink financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioDlink leadership team

Management profile

Number of profiles

Profiles9 records

BioDlink funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioDlink M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioDlink

What does BioDlink do?

BioDlink is a biologics Contract Development and Manufacturing Organization (CDMO) providing one-stop services spanning antibody R&D, cell line development, ADC conjugation process development, drug substance and drug product manufacturing, lyophilization, analytical method development, technology transfer, and regulatory affairs support. The company operates an integrated ADC/XDC CRDMO platform with over 20,000 L of monoclonal antibody manufacturing capacity and 960 kg of ADC drug substance capacity, serving global biopharmaceutical clients from early R&D through commercial manufacturing.

Is BioDlink a public or private company?

BioDlink is a public company. It is classified as public and is currently operating.

When was BioDlink founded?

BioDlink was founded in 2010. It employs 51 to 100 people.

Where is BioDlink based?

BioDlink is headquartered in Suzhou, China, in the Asia region.

How does BioDlink make money?

Two revenue lines are on record. CDMO/CMO Services are the primary driver. The others are product Sales.

Who are BioDlink's main competitors?

Broad incumbents on record are Lonza Biologics, WuXi Biologics, Samsung Biologics, Patheon (Thermo Fisher) and Catalent (Novo Holdings). Direct peers are Pharmaron, TOT Biopharma, AGC Biologics, WuXi XDC and Genscript ProBio.

Does BioDlink have an API?

No public API is recorded for BioDlink.

What industry is BioDlink in?

BioDlink's product category is Biologics Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACWuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO LeadershipWuXi XDC reported a strong first-half 2026 financial performance, with total revenue increasing by 37.0% year-over-year to RMB 3,701.4 million and adjusted net profit rising by 37.4% to RMB 1,027.3 million. The company expanded its global customer base to over 810 companies and grew its service backlog to approximately US$2.0 billion, driven by increased demand for bioconjugate CRDMO services and the integration of BioDlink.PR NewswireWuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO LeadershipWuXi XDC reported H1 2026 revenue of RMB 3,701.4 million, up 37% year-over-year, and adjusted net profit of RMB 1,027.3 million, up 37.4%. Gross profit margin improved to 37%, and the service backlog grew to US$2.0 billion. The company plans further capacity expansions in Wuxi and Jiangyin.PR NewswireStronger Together, Shaping the Future | WuXi XDC and BioDlink Successfully Concluded 2026 Open DayWuXi XDC and BioDlink jointly hosted their 2026 Open Day, marking the first major customer-facing event since BioDlink became a controlled subsidiary of WuXi XDC, bringing together biotech customers and industry leaders in Suzhou, China. The event featured the official launch of the "Stronger Together" initiative and showcased the combined integrated ADC/XDC CRDMO platform aimed at accelerating development and commercialization of next-generation bioconjugate therapies. The companies reaffirmed their commitment to expanding integrated capabilities and empowering global innovators to bring transformative therapies to patients worldwide.PR Newswire APACWuXi XDC and BioDlink Successfully Concluded 2026 Open Day - PR Newswire APACWuXi XDC and BioDlink hosted their 2026 Open Day in Suzhou, marking the first joint event since BioDlink became a controlled subsidiary. The event launched the "Stronger Together" initiative and featured panel discussions on XDC collaboration models. The companies will continue expanding integrated CRDMO capabilities.MarketScreenerWuXi XDC Cayman Inc. completed the acquisition of 60% stake in BioDlink International Company Limited from a group of shareholders.WuXi XDC Cayman Inc. completed the acquisition of a 60% stake in BioDlink International Company Limited from a group of shareholders on March 31, 2026. The offer received acceptances for 463,672,734 offer shares, representing approximately 60% of issued share capital, and the transaction is expected to close on March 31, 2026.PR NewswireBioDlink Named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence AwardsBioDlink has been named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence Awards, organized by IMAPAC, recognizing its innovation in complex biologics and antibody-drug conjugate (ADC) development. The award highlights the company's proprietary technology platforms—including GL-DisacLink®, BDKcell™, and BDKLyo—alongside its scalable manufacturing infrastructure and a quality management system that has successfully passed over 100 client and regulatory audits. The recognition positions BioDlink as a growing trusted development and manufacturing partner for global biopharmaceutical innovators.PR Newswire APACBioDlink Named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence AwardsBioDlink, a contract development and manufacturing organization specializing in biologics and antibody-drug conjugates, was named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence Awards organized by IMAPAC. The award recognizes the company's proprietary technology platforms, scalable manufacturing capabilities, and quality management system that has successfully completed over 100 client and regulatory audits. The recognition highlights BioDlink's growing role as a development and manufacturing partner for global biopharmaceutical companies, with the company operating four commercial manufacturing lines across facilities in China.European BiotechnologySolutions-Based Thinking: BioDlink’s Model for Successful CDMO PartnershipsIn an interview during J.P. Morgan Week in San Francisco, Dr. Jian Zhang, Acting CEO of BioDlink, outlined how the company's partnership-first CDMO model helps European biotech companies compete against Chinese firms that now account for 54% of ADC molecules in Phase 1 and 2 development globally. BioDlink, which pivoted from biosimilars to ADC-focused CDMO services in 2020, has demonstrated its value through successful client outcomes including Profound Bio's acquisition by Genmab for €1.8 billion and multiple out-licensing deals with major pharmaceutical companies. The company has developed proprietary technologies including a conjugation platform, a high-performing cell line achieving 8-10 grams per liter titer, and a digital lyophilization modeling platform, while maintaining strong ESG credentials including a Wind ESG double-A rating.PR NewswireBioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical TrialsBioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for enabling IND approval for KH815, the world's first dual-payload antibody-drug conjugate to enter clinical development. As Kanghong's CDMO partner, BioDlink completed process development, manufacturing, and regulatory submission activities 1.5 months ahead of schedule, supporting the full development lifecycle including analytical method development and formulation research. The successful progression of KH815 underscores the growing potential of dual-payload ADC technologies and highlights the value of close industry-academia collaboration.PR NewswireBioDlink Modernizes Quality Management with Successful Go-Live of Veeva QMSBioDlink has successfully implemented Veeva QMS, a cloud-based quality management system, with an official go-live on January 29, 2026, marking a key milestone in its quality digitalization strategy. The initial deployment covers four core quality processes—Deviation Management, Change Management, Laboratory Investigation, and CAPA Management—establishing a digital, standardized, end-to-end quality operations framework to support its GMP-compliant biologics manufacturing operations. Additional modules including Quality Risk Management, Audit Management, and Supplier Management are planned for future phases as part of BioDlink's roadmap toward comprehensive GMP digitalization.